Prognostic significance of microRNA-100 in solid tumors: an updated meta-analysis.
OBJECTIVE
The aim of this study was to identify prognostic significance of microRNA-100 (miR-100) in solid tumor.


METHODS
Literature search was conducted in databases such as PubMed, Embase, and Web of Science, using the following words "(microRNA-100 OR miR-100 OR mir100) AND (tumor OR neoplasm OR cancer OR carcinoma OR malignancy)." The search was updated up until July 10, 2016. Newcastle-Ottawa scale was used to evaluate the quality of studies. Pooled hazard ratio (HR) with 95% confidence interval (CI) for patients' survival was calculated by using a fixed-effects or a random-effects model on the basis of heterogeneity. Subgroup analysis, sensitive analysis, and meta-regression were used to investigate the sources of heterogeneity. Publication bias was evaluated by using Begg's and Egger's tests.


RESULTS
A total of 16 articles with 1,501 patients were included in the present meta-analysis. It was demonstrated that a lower expression of miR-100 plays a negative role in the overall survival (OS) of patients with solid tumor (HR =1.92; 95% CI =1.25-2.94). In addition, the association between miR-100 and prognosis was also revealed in the following subgroups: non-small-cell lung cancer (NSCLC; HR =2.46; 95% CI =1.98-3.06), epithelial ovarian cancer (EOC; HR =2.29, 95% CI =1.72-3.04), and bladder cancer (BC; HR =4.14, 95% CI =1.85-9.27).


CONCLUSIONS
This meta-analysis indicates that lower expression of miR-100 is related to poorer OS in patients with solid tumor, especially in those with NSCLC, EOC, and BC. MiR-100 is a promising prognosis predictor and may be a potential target for therapy in the future.
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Jiangfeng
J
Wang
School of Medicine, University of Washington, Seattle, WA, USA.
Miao
M
Yu
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Shanghui
S
Guan
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Guangyu
G
Zhang
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Jianbo
J
Wang
Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Yufeng
Y
Cheng
meta-analysis; microRNA-100; prognosis